Comparative Pharmacology
Head-to-head clinical analysis: CYTOXAN LYOPHILIZED versus HEPZATO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTOXAN LYOPHILIZED versus HEPZATO.
CYTOXAN (LYOPHILIZED) vs HEPZATO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclophosphamide is an alkylating agent that cross-links DNA, inhibiting DNA replication and transcription. It also has immunosuppressive effects by suppressing B and T lymphocyte function.
HEPZATO (melphalan) is a nitrogen mustard alkylating agent that crosslinks DNA strands, inhibiting DNA replication and transcription, leading to cell death.
500-1000 mg/m² IV every 2-4 weeks, or 60-120 mg/m² IV daily for 2-3 days, or 500-750 mg/m² IV every 3 weeks. Oral: 50-200 mg daily as continuous therapy.
Melphalan 3 mg/kg ideal body weight via hepatic artery infusion over 15-30 minutes followed by hemofiltration, administered once per treatment cycle.
None Documented
None Documented
Cyclophosphamide: 4-8 hours (dose-dependent, prolonged in hepatic impairment). Active metabolites (e.g., phosphoramide mustard): 6-12 hours.
The terminal elimination half-life of melphalan is approximately 1.5 hours following intravenous administration. This short half-life necessitates regional delivery (hepatic arterial infusion) to achieve high local concentrations with limited systemic exposure.
Renal: 30-60% of unchanged drug and metabolites (primarily phosphoramide mustard and acrolein). Biliary/fecal: minor (<10%).
HEPZATO (melphalan hydrochloride) for injection is renally eliminated; approximately 20-30% of the administered dose is excreted unchanged in the urine over 24 hours. The major metabolites are hydrolysis products, which are also excreted renally. Biliary/fecal elimination accounts for less than 10% of the dose.
Category C
Category C
Alkylating Agent
Alkylating Agent